Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms. - Wikidata - awgldk - TriplyDB

Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms.

Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms.

http://www.wikidata.org/entity/Q37226551

about

Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies Mesothelin as a potential therapeutic target in human cholangiocarcinoma.A smac mimetic reduces TNF related apoptosis inducing ligand (TRAIL)-induced invasion and metastasis of cholangiocarcinoma cells Differential gene expression profiling of cultured neu-transformed versus spontaneously-transformed rat cholangiocytes and of corresponding cholangiocarcinomas Periostin in intrahepatic cholangiocarcinoma: pathobiological insights and clinical implications.Tumour cell-derived extracellular vesicles interact with mesenchymal stem cells to modulate the microenvironment and enhance cholangiocarcinoma growth A mouse model of cholestasis-associated cholangiocarcinoma and transcription factors involved in progression.High level of urokinase plasminogen activator contributes to cholangiocarcinoma invasion and metastasis.Expression of Molecular Differentiation Markers Does Not Correlate with Histological Differentiation Grade in Intrahepatic Cholangiocarcinoma.Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer.Clinicopathological Significance of Osteopontin in Cholangiocarcinoma Cases.Genetics of biliary tract cancers and emerging targeted therapies.Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities.The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma.miR-17-92 cluster promotes cholangiocarcinoma growth: evidence for PTEN as downstream target and IL-6/Stat3 as upstream activator.Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.Wip1 is associated with tumorigenity and metastasis through MMP-2 in human intrahepatic cholangiocarcinoma.Cholangiocarcinoma pathogenesis: Role of the tumor microenvironment.Novel organotypic culture model of cholangiocarcinoma progression.Staging, prognostic factors and adjuvant therapy of intrahepatic cholangiocarcinoma after curative resection.Extracellular vesicles carry microRNA-195 to intrahepatic cholangiocarcinoma and improve survival in a rat model.Transforming Growth Factors α and β Are Essential for Modeling Cholangiocarcinoma Desmoplasia and Progression in a Three-Dimensional Organotypic Culture Model.Diagnostic and Prognostic Role of 18-FDG PET/CT in the Management of Resectable Biliary Tract Cancer.Epigenetic Silencing of miRNA-34a in Human Cholangiocarcinoma via EZH2 and DNA Methylation: Impact on Regulation of Notch Pathway.The microRNA-15a-PAI-2 axis in cholangiocarcinoma-associated fibroblasts promotes migration of cancer cells.The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer.Overexpression of long non-coding RNA CRNDE facilitates epithelial-mesenchymal transition and correlates with poor prognosis in intrahepatic cholangiocarcinoma.Overexpression of periostin and distinct mesothelin forms predict malignant progression in a rat cholangiocarcinoma model.Intraarterial 5-fluorouracil and interferon therapy is safe and effective for nonresectable biliary tract adenocarcinoma.Nab-paclitaxel is effective against intrahepatic cholangiocarcinoma via disruption of desmoplastic stroma.The expression of S100A4 protein in human intrahepatic cholangiocarcinoma: clinicopathologic significance and prognostic value

P2860

Q27002547-83F49DDB-53BD-45F3-AA11-CF0FF6700AE9 Q34167021-E3DC920A-6FED-4E19-A9A1-415BDEFAB834 Q34212347-D2C05DB9-A149-4B74-AFFC-0AD8BE9F8847 Q34311704-DA0C35C0-4FCC-461F-998C-A9C83B94854F Q34673957-66A03904-F75F-48C6-8A5A-60EC8DF67155 Q34811043-F73FEDAC-CF1A-4B3B-9CEB-B2045BF9DF08 Q35085932-4D27AF25-61F2-4154-81A8-162C0F39FF30 Q35681554-497BA702-8E3E-4A6F-AC3C-AC57E6DCFF7C Q36046443-CCBD8F20-84AF-402A-ACF3-C50A0B277BB2 Q36545163-56A3E078-41C8-4D4F-BA53-DF0A414DC2E8 Q36683019-64842A44-DE8E-45F9-A3D0-EBA9B803E867 Q37113845-70A4CD85-3821-449E-8EB7-24559DA9FD3D Q37765099-D1C70A80-D62A-4830-B685-226A50A9EFC9 Q37833005-A77654CF-E730-4848-A1BB-AC1EBD2979BF Q37964960-8F301FEA-72CF-401B-AAFD-D77B93B22D48 Q38954890-4D834205-3452-4260-906C-54FC6FEBD1EB Q39683530-00C10BBC-F099-4833-8607-302F43D5BA67 Q41345284-04955C76-6DAE-4CF0-8111-3BCD29910165 Q42029380-3B70A225-AF0A-4944-A62F-7E3DFB49567C Q42271933-4A1EDDB7-5B1B-4C45-AC57-DA3DA11D7ABE Q44508765-D05D400D-AC2F-4D54-9F7B-6C520962EAC9 Q45039242-4282F676-B2FD-44D1-B159-6FFA7D7D2E98 Q45055057-9856DC00-05A8-4288-AED5-C1F5642039A9 Q47640222-2B73BEC6-D92E-4D4A-A683-E83B142C24A4 Q47783721-1A430FC6-69F5-4640-898C-81076800BA6C Q48217057-8C39C64C-017C-4856-B342-68B7605A3E98 Q50350640-39ED0131-D5DB-4AC0-A0C6-3D8550A152DB Q52647722-38C8FC9B-71C6-44C2-9AA2-51CAD7F1AFC2 Q52733584-EF30A23A-A7CF-49B8-849C-8830EA6DAD54 Q53573044-85BF636A-45FF-41EE-9CD5-93603B5A6E65 Q55497250-F1C2770E-EDF8-4B50-BC07-6670D09E268F Q57148077-3B624F0F-7177-4C80-9F56-1D78684D77DB

P2860

Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms.

http://www.wikidata.org/entity/Q37226551

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms.

@en

Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms.

@nl

type

label

Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms.

@en

Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms.

@nl

prefLabel

Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms.

@en

Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms.

@nl

P1433

Q37226551-48CF617D-A47E-4129-ADED-F9CDF0F70548

P1476

Q37226551-6422624C-4C0B-4F34-97A3-EF5CBA13E31A

P2093

Q37226551-5CE3027A-0457-4CA8-B5E1-E269090C8778

Q37226551-AD4906BC-58F6-4A5A-823F-34A5A047A726

Q37226551-C6E493D1-DCD6-4837-82C9-601777A0328E

Q37226551-C7B1E7FA-E0FB-47AC-8A86-4493F90B0CA8

P2860

Q37226551-074701CC-DE7C-45AA-BDF3-220860752C86

Q37226551-08B9CD0C-6D90-4A5C-990B-7D30F1F0508C

Q37226551-1717C3A8-83BD-4459-939A-CD3C0D43052C

Q37226551-177D07D6-A61A-4A68-A120-55FAFC9A7C74

Q37226551-184666C2-EE59-42BF-968D-6341D353F5AB

Q37226551-1D036E2E-7E09-4882-9874-B198453D3A93

Q37226551-1DEA3091-70A5-428A-BC7C-675C63BB839E

Q37226551-1F17AC60-D7D0-4006-8625-F33BEA9CF07A

Q37226551-231942A5-75F9-4E5B-804E-9A51BD7C7022

Q37226551-285EF387-9DB0-4F1A-88F7-113E7CB54B8A

P304

Q37226551-54A9DB80-8608-4F7E-B0B5-6398FFBB3F21

P31

Q37226551-1F4710BA-F7F4-47AE-8514-EA74B201CC0E

P356

Q37226551-468B9FF7-427B-4E71-BAB3-D1B3FF4E210B

P407

Q37226551-3EAFB584-616E-470C-85AA-08D2A4EA745B

P433

Q37226551-B97DE306-025F-42D1-87B0-82B902BC0D4B

P478

Q37226551-9391A50B-0B6E-404E-AFB4-DE5CBCB8ABD3

P50

Q37226551-9290BD93-F95F-4543-98E1-E1E1BBDBCA19

Q37226551-EF04CB22-2356-45C7-ACEC-ED43078CFA12

P577

Q37226551-621ED50D-9C16-47DA-A598-E1B7B65426D5

P698

Q37226551-5F509CBD-2B63-482F-A682-841FB39B7B57

P921

Q37226551-0630086E-EA44-43E8-8570-DCCA03966170

P932

Q37226551-6D60A2E7-4C00-448D-97F1-3A3BC63D96FD

P356

J.CGH.2009.08.023

P1433

Clinical Gastroenterology and Hepatology

P1476

Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms

@en

P2093

Alphonse E Sirica

http://www.w3.org/2001/XMLSchema#string

Deanna J W Campbell

http://www.w3.org/2001/XMLSchema#string

Jennifer L Dewitt

http://www.w3.org/2001/XMLSchema#string

Jorge A Almenara

http://www.w3.org/2001/XMLSchema#string

P2860

Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma

Proliferating bile duct epithelial cells are a major source of connective tissue growth factor in rat biliary fibrosis

The membrane mucin Muc4 inhibits apoptosis induced by multiple insults via ErbB2-dependent and ErbB2-independent mechanisms

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy.

Human gastrointestinal neoplasia-associated myofibroblasts can develop from bone marrow-derived cells following allogeneic stem cell transplantation.

Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy.

Biliary cancer growth factor pathways, cyclo-oxygenase-2 and potential therapeutic strategies.

Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway.

Emerging roles of MUC4 in cancer: a novel target for diagnosis and therapy.

P304

S68-78

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CGH.2009.08.023

http://www.w3.org/2001/XMLSchema#string

P407

P433

11 Suppl

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Olorunseun O. Ogunwobi

Catherine I Dumur

P577

2009-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19896103

http://www.w3.org/2001/XMLSchema#string

P921

cholangiocarcinoma

P932

3795391

http://www.w3.org/2001/XMLSchema#string